Hybrid Revascularization or Conventional Surgery: History Is Still Being Written

Hybrid revascularization seems to achieve results similar to those of conventional myocardial revascularization surgery at 5 years, although studies published so far do not seem to be enough for a definitive answer.

revascularizacion incompleta en cirugia no cardiacaThis new work, soon to be published in J Am Coll Cardiol Intv, has had promising results in selected patients with multivessel disease; however, we will have to wait for adequately powered randomized studies to add hybrid revascularization to our therapeutic toolbox.

 

One-year results from the POL-MIDES (HYBRID) study showed the feasibility of hybrid revascularization among 200 patients with anterior descending artery lesion and a lesion >70% in at least one other major epicardial vessel. All patients were candidates for surgery or angioplasty.


Read also: Do the Best Coronary Revascularization Prior TAVR.


This new publication brings us the 5-year results, which showed similar mortality among hybrid revascularization and conventional myocardial revascularization surgery (6.4% vs. 9.2%; p = 0.69) as well as similar rates of acute myocardial infarction (4.3% vs. 7.2%; p = 0.30), repeat revascularization (37.2% vs. 45.4%; p = 0.38), stroke (2.1% vs. 4.1%; p = 0.35), or combined events (45.2% vs. 45.4%; p = 0.39).

 

No differences between strategies were observed, either, after patients were stratified by both EuroSCORE and SYNTAX score tertiles.

 

In reality, this technique entails a certain learning curve for surgeons, and not everyone is willing to try it, particularly if there are no significant differences in outcomes when compared with conventional surgery.


Read also: Complete Revascularization Is Beneficial in Acute MI with Cardiogenic Shock.


This is also added to practical limitations as regards logistics, such as a lack of hybrid operation rooms versus a procedure than can be performed in stages, cooperation and collaboration of surgical and interventional teams, risk of bleeding due to the use of antiplatelet and antithrombotic therapy, and difficulties in the assessment of cost-effectiveness. In conclusion, the use of hybrid revascularization will remain uncommon until there is more convincing evidence in its favor.

 

Original title: Hybrid Coronary Revascularization in Selected Patients with Multivessel Disease – 5 Year Clinical Outcomes of the Prospective Randomized Pilot Study.

Reference: Tajstra M et al. J Am Coll Cardiol Intv 2018; Epub ahead of print.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....